Docosahexaenoic acid: A natural powerful adjuvant that improves efficacy for anticancer treatment with no adverse effects

BioFactors

Volumn 37, Issue 6, 2011, Pages 399-412

  Siddiqui, Rafat A ^a,b   Harvey, Kevin A ^a   Xu, Zhidong ^a   Bammerlin, Elaine M ^a   Walker, Candace ^a   Altenburg, Jeffrey D ^a  

^a INDIANA UNIVERSITY HEALTH   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Docosahexaenoic acid; Drug synergy; N 3 fatty acids

Indexed keywords

ACETYLSALICYLIC ACID; ADJUVANT; ARSENIC TRIOXIDE; CELECOXIB; CISPLATIN; CURCUMIN; DOCETAXEL; DOCOSAHEXAENOIC ACID; DOXORUBICIN; EMODIN; FLUOROURACIL; GENISTEIN; INDOMETACIN; PACLITAXEL; PIROXICAM; RECOMBINANT GAMMA INTERFERON; SELENIUM; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CELL SURVIVAL; CHEMOSENSITIVITY; COLORECTAL CANCER; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TUMOR LEVEL; DRUG UPTAKE; HUMAN; LEUKEMIA CELL; LIPID COMPOSITION; LIPID PEROXIDATION; LUNG SMALL CELL CANCER; MEMBRANE DAMAGE; MITOCHONDRIAL MEMBRANE POTENTIAL; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; T CELL LEUKEMIA; TREATMENT RESPONSE; TUMOR CELL LINE; UTERINE CERVIX CARCINOMA;

ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOCOSAHEXAENOIC ACIDS; DRUG SYNERGISM; HUMANS; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 84155170825     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.181     Document Type: Review

References (113)

1. Salem, N. J., Kim, H. Y., Yergey, J. A., in Simopoulos, A., Kifer, R., Martin, R., and Barlow, S., Eds. ( 1986) The Health Effects of Polyunsaturated Fatty Acid in Seafoods, Academic Press, New York, pp. 363-371.
2. Stillwell, W. and Wassall, S. R. ( 2003) Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem. Phys. Lipids 126, 1-27.
3. Ursin, V. M. ( 2003) Modification of plant lipids for human health: development of functional land-based omega-3 fatty acids. J. Nutr. 133, 4271-4274.
4. Clemente, T. E. and Cahoon, E. B. ( 2009) Soybean oil: genetic approaches for modification of functionality and total content. Plant Physiol. 151, 1030-1040.
5. Venegas-Caleron, M., Sayanova, O., and Napier, J. A. ( 2010) An alternative to fish oils: Metabolic engineering of oil-seed crops to produce omega-3 long chain polyunsaturated fatty acids. Prog. Lipid Res. 49, 108-119.
6. Kaizer, L., Boyd, N. F., Kriukov, V., and Tritchler, D. ( 1989) Fish consumption and breast cancer risk: an ecological study. Nutr. Cancer 12, 61-68.
7. Vogel, V. G., and McPherson, R. S. ( 1989) Dietary epidemiology of colon cancer. Hematol. Oncol. Clin. North Am. 3, 35-63.
8. Berg, J. P., Glattre, E., Haldorsen, T., Hostmark, A. T., Bay, I. G., Johansen, A. F., and Jellum, E. ( 1994) Longchain serum fatty acids and risk of thyroid cancer: a population-based case-control study in Norway. Cancer Causes Control 5, 433-439.
9. Schloss, I., Kidd, M. S., Tichelaar, H. Y., Young, G. O., O'Keefe, S. J. ( 1997) Dietary factors associated with a low risk of colon cancer in coloured west coast fishermen. S. Afr. Med. J. 87, 152-158.
10. Rose, D. P., and Connolly, J. M. ( 1993) Effects of dietary omega-3 fatty acids on human breast cancer growth and metastases in nude mice. J. Natl Cancer Inst. 85, 1743-1747.
11. Connolly, J. M., Gilhooly, E. M., and Rose, D. P. ( 1999) Effects of reduced dietary linoleic acid intake, alone or combined with an algal source of docosahexaenoic acid, on MDA-MB-231 breast cancer cell growth and apoptosis in nude mice. Nutr. Cancer 35, 44-49.
12. Rose, D. P., and Connolly, J. M. ( 1999) Antiangiogenicity of docosahexaenoic acid and its role in the suppression of breast cancer cell growth in nude mice. Int. J. Oncol. 15, 1011-1015.
13. Calder, P. C. ( 2007) Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 77, 327-335.
14. Siddiqui, R. A., Harvey, K. A., and Zaloga, G. P. ( 2008) Modulation of enzymatic activities by n-3 polyunsaturated fatty acids to support cardiovascular health. J. Nutr. Biochem. 19, 417-437.
15. Simopoulos, A. P. ( 2009) Omega-6/omega-3 essential fatty acids: biological effects. World Rev. Nutr. Diet 99, 1-16.
16. Picq, M., Chen, P., Perez, M., Michaud, M., Vericel, E., Guichardant, M., and Lagarde, M. ( 2010) DHA metabolism: targeting the brain and lipoxygenation. Mol. Neurobiol. 42, 48-51.
17. Simopoulos, A. P. ( 2004) The traditional diet of Greece and cancer. Eur. J. Cancer Prev. 13, 219-230.
18. Loewe, S. ( 1953) The problem of synergism and antagonism of combined drugs. Arzneimittelforschung 3, 285-290.
19. Webb, J. L. ( 1963) Enzyme and Metabolic Inhibitors, Academic Press, New York.
20. Chou, T. C., and Talalay, P. ( 1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55.
21. Tallarida, R. J. ( 2002) The interaction index: a measure of drug synergism. Pain 98, 163-168.
22. Burns, C. P., Luttenegger, D. G., Dudley, D. T., Buettner, G. R., and Spector, A. A. ( 1979) Effect of modification of plasma membrane fatty acid composition on fluidity and methotrexate transport in L1210 murine leukemia cells. Cancer Res. 39, 1726-1732.
23. Guffy, M. M., North, J. A., and Burns, C. P. ( 1984) Effect of cellular fatty acid alteration on adriamycin sensitivity in cultured L1210 murine leukemia cells. Cancer Res. 44, 1863-1866.
24. Zijlstra, J. G., de Vries, E. G., Muskiet, F. A., Martini, I. A., Timmer-Bosscha, H., and Mulder, N. H. ( 1987) Influence of docosahexaenoic acid in vitro on intracellular adriamycin concentration in lymphocytes and human adriamycin-sensitive and -resistant small-cell lung cancer cell lines, and on cytotoxicity in the tumor cell lines. Int. J. Cancer 40, 850-856.
25. Ikushima, S., Fujiwara, F., Todo, S., and Imashuku, S. ( 1991) Effects of polyunsaturated fatty acids on vincristine-resistance in human neuroblastoma cells. Anticancer Res. 11, 1215-1220.
26. Das, U. N., Madhavi, N., Sravan Kumar, G., Padma, M., and Sangeetha, P. ( 1998) Can tumour cell drug resistance be reversed by essential fatty acids and their metabolites?. Prostaglandins Leukot. Essent. Fatty Acids 58, 39-54.
27. Jing, Y., Dai, J., Chalmers-Redman, R. M., Tatton, W. G., and Waxman, S. ( 1999) Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 94, 2102-2111.
28. Miller, W. H., Jr., Schipper, H. M., Lee, J. S., Singer, J., and Waxman, S. ( 2002) Mechanisms of action of arsenic trioxide. Cancer Res. 62, 3893-3903.
29. Chen, G. Q., Zhu, J., Shi, X. G., Ni, J. H., Zhong, H. J., Si, G. Y., Jin, X. L., Tang, W., Li, X. S., Xong, S. M., Shen, Z. X., Sun, G. L., Ma, J., Zhang, P., Zhang, T. D., Gazin, C., Naoe, T., Chen, S. J., Wang, Z. Y., and Chen, Z. ( 1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88, 1052-1061.
30. Chen, G. Q., Shi, X. G., Tang, W., Xiong, S. M., Zhu, J., Cai, X., Han, Z. G., Ni, J. H., Shi, G. Y., Jia, P. M., Liu, M. M., He, K. L., Niu, C., Ma, J., Zhang, P., Zhang, T. D., Paul, P., Naoe, T., Kitamura, K., Miller, W., Waxman, S., Wang, Z. Y., de The, H., Chen, S. J., and Chen, Z. ( 1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89, 3345-3353.
31. Kitamura, K., Kiyoi, H., Yoshida, H., Tobita, T., Takeshita, A., Ohno, R., and Naoe, T. ( 1997) New retinoids and arsenic compounds for the treatment of refractory acute promyelocytic leukemia: clinical and basic studies for the next generation. Cancer Chemother. Pharmacol. 40 Suppl: S36-41.
32. Huang, X. J., Wiernik, P. H., Klein, R. S., and Gallagher, R. E. ( 1999) Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases. Med. Oncol. 16, 58-64.
33. Seol, J. G., Park, W. H., Kim, E. S., Jung, C. W., Hyun, J. M., Kim, B. K., and Lee, Y. Y. ( 1999) Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. Biochem. Biophys. Res. Commun. 265, 400-404.
34. Zhang, T. C., Cao, E. H., Li, J. F., Ma, W., and Qin, J. F. ( 1999) Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur. J. Cancer 35, 1258-1263.
35. Uslu, R., Sanli, U. A., Sezgin, C., Karabulut, B., Terzioglu, E., Omay, S. B., and Goker, E. ( 2000) Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin. Cancer Res. 6, 4957-4964.
36. Hyun Park, W., Hee Cho, Y., Won Jung, C., Oh Park, J., Kim, K., Hyuck Im, Y., Lee, M. H., Ki Kang, W., and Park, K. ( 2003) Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem. Biophys. Res. Commun. 300, 230-235.
37. Sturlan, S., Baumgartner, M., Roth, E., and Bachleitner-Hofmann, T. ( 2003) Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. Blood 101, 4990-4997.
38. Brown, M., Bellon, M., and Nicot, C. ( 2007) Emodin and DHA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-I-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1. Blood 109, 1653-1659.
39. Baumgartner, M., Sturlan, S., Roth, E., Wessner, B., Bachleitner-Hofmann, T. ( 2004) Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. Int. J. Cancer 112, 707-712.
40. Burns, C. P., and North, J. A. ( 1986) Adriamycin transport and sensitivity in fatty acid-modified leukemia cells. Biochim. Biophys. Acta 888, 10-17.
41. Liu, Q. Y., and Tan, B. K. ( 2000) Effects of cis-unsaturated fatty acids on doxorubicin sensitivity in P388/DOX resistant and P388 parental cell lines. Life Sci. 67, 1207-1218.
42. Benchekroun, M. N., Pourquier, P., Schott, B., and Robert, J. ( 1993) Doxorubicin-induced lipid peroxidation and glutathione peroxidase activity in tumor cell lines selected for resistance to doxorubicin. Eur. J. Biochem. 211, 141-146.
43. Maheo, K., Vibet, S., Steghens, J. P., Dartigeas, C., Lehman, M., Bougnoux, P., and Gore, J. ( 2005) Differential sensitization of cancer cells to doxorubicin by DHA: a role for lipoperoxidation. Free Radic. Biol. Med. 39, 742-751.
44. Vibet, S., Goupille, C., Bougnoux, P., Steghens, J. P., Gore, J., and Maheo, K. ( 2008) Sensitization by docosahexaenoic acid (DHA) of breast cancer cells to anthracyclines through loss of glutathione peroxidase (GPx1) response. Free Radic. Biol. Med. 44, 1483-1491.
45. Germain, E., Chajes, V., Cognault, S., Lhuillery, C., and Bougnoux, P. ( 1998) Enhancement of doxorubicin cytotoxicity by polyunsaturated fatty acids in the human breast tumor cell line MDA-MB-231, relationship to lipid peroxidation. Int. J. Cancer 75, 578-583.
46. Menendez, J. A., del Mar Barbacid, M., Montero, S., Sevilla, E., Escrich, E., Solanas, M., Cortes-Funes, H., and Colomer, R. ( 2001) Effects of gamma-linolenic acid and oleic acid on paclitaxel cytotoxicity in human breast cancer cells. Eur. J. Cancer 37, 402-413.
47. Menendez, J. A., Lupu, R., and Colomer, R. ( 2005) Exogenous supplementation with omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA; 22, 6n-3) synergistically enhances taxane cytotoxicity and downregulates Her-2/neu (c-erbB-2) oncogene expression in human breast cancer cells. Eur. J. Cancer Prev. 14, 263-270.
48. Timmer-Bosscha, H., Hospers, G. A., Meijer, C., Mulder, N. H., Muskiet, F. A., Martini, I. A., Uges, D. R., de Vries, E. G. ( 1989) Influence of docosahexaenoic acid on cisplatin resistance in a human small cell lung carcinoma cell line. J. Natl Cancer Inst. 81, 1069-1075.
49. Ding, W. Q., Liu, B., Vaught, J. L., Palmiter, R. D., and Lind, S. E. ( 2006) Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells. Mol. Cancer Ther. 5, 1864-1872.
50. Tuller, E. R., Brock, A. L., Yu, H., Lou, J. R., Benbrook, D. M., and Ding, W. Q. ( 2009) PPARalpha signaling mediates the synergistic cytotoxicity of clioquinol and docosahexaenoic acid in human cancer cells. Biochem. Pharmacol. 77, 1480-1486.
51. Padmanabhan, G., Becue, I., Smith, J., in Klauss, E., Florey, E., Eds. ( 1989) Analytical Profiles of Drug Substances, Academic Press, New York, pp. 57-90.
52. Davison, Z., Dutkowski, C., Gee, J. M., Nicholson, R. I., and Heard, C. M. ( 2008) In vitro effects on MCF-7 breast cancer cells of signal transduction inhibitor/tamoxifen/eicosapentaenoic acid combinations and their simultaneous delivery across skin. Pharm. Res. 25, 2516-2525.
53. Hartmann, J. T., Kohne, C. H., Schmoll, H. J., Daikeler, T., Kanz, L., and Bokemeyer, C. ( 1998) Is continuous 24-hour infusion of 5-fluorouracil plus high-dose folinic acid effective in patients with progressive or recurrent colorectal cancer? A phase II study. Oncology 55, 320-325.
54. Petrelli, N., Douglass, H. O., Jr., Herrera, L., Russell, D., Stablein, D. M., Bruckner, H. W., Mayer, R. J., Schinella, R., Green, M. D., Muggia, F. M., et al. ( 1989) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J. Clin. Oncol. 7, 1419-1426.
55. Valone, F. H., Friedman, M. A., Wittlinger, P. S., Drakes, T., Eisenberg, P. D., Malec, M., Hannigan, J. F., Brown, B. W., Jr. ( 1989) Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group. J. Clin. Oncol. 7, 1427-1436.
56. Bunz, F., Hwang, P. M., Torrance, C., Waldman, T., Zhang, Y., Dillehay, L., Williams, J., Lengauer, C., Kinzler, K. W., and Vogelstein, B. ( 1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest. 104, 263-269.
57. Calviello, G., Di Nicuolo, F., Serini, S., Piccioni, E., Boninsegna, A., Maggiano, N., Ranelletti, F. O., and Palozza, P. ( 2005) Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5-fluorouracil. Cancer Chemother. Pharmacol. 55, 12-20.
58. Zhou, Z., Zhang, L., Mu, Q., Lou, Y., Gong, Z., Shi, Y., Ouyang, G., and Zhang, Y. ( 2009) The effect of combination treatment with docosahexaenoic acid and 5-fluorouracil on the mRNA expression of apoptosis-related genes, including the novel gene BCL2L12, in gastric cancer cells. In Vitro Cell Dev. Biol. Anim. 45, 69-74.
59. Tjandrawinata, R. R., Dahiya, R., Hughes-Fulford, M. ( 1997) Induction of cyclo-oxygenase-2 mRNA by prostaglandin E2 in human prostatic carcinoma cells. Br. J. Cancer 75, 1111-1118.
60. Taketo, M. M. ( 1998) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl Cancer Inst. 90, 1529-1536.
61. Dannenberg, A. J., Altorki, N. K., Boyle, J. O., Dang, C., Howe, L. R., Weksler, B. B., and Subbaramaiah, K. ( 2001) Cyclo-oxygenase 2, a pharmacological target for the prevention of cancer. Lancet Oncol. 2, 544-551.
62. Hawk, E. T., Viner, J. L., Dannenberg, A., and DuBois, R. N. ( 2002) COX-2 in cancer--a player that's defining the rules. J. Natl Cancer Inst. 94, 545-546.
63. McCormick, D. L., Rao, K. V., Steele, V. E., Lubet, R. A., Kelloff, G. J., and Bosland, M. C. ( 1999) Chemoprevention of rat prostate carcinogenesis by 9-cis-retinoic acid. Cancer Res. 59, 521-524.
64. Rao, K. V., Johnson, W. D., Bosland, M. C., Lubet, R. A., Steele, V. E., Kelloff, G. J., and McCormick, D. L. ( 1999) Chemoprevention of rat prostate carcinogenesis by early and delayed administration of dehydroepiandrosterone. Cancer Res. 59, 3084-3089.
65. Narayanan, B. A., Narayanan, N. K., Simi, B., and Reddy, B. S. ( 2003) Modulation of inducible nitric oxide synthase and related proinflammatory genes by the omega-3 fatty acid docosahexaenoic acid in human colon cancer cells. Cancer Res. 63, 972-979.
66. Swamy, M. V., Cooma, I., Patlolla, J. M., Simi, B., Reddy, B. S., and Rao, C. V. ( 2004) Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment. Mol. Cancer Ther. 3, 215-221.
67. Narayanan, N. K., Narayanan, B. A., and Reddy, B. S. ( 2005) A combination of docosahexaenoic acid and celecoxib prevents prostate cancer cell growth in vitro and is associated with modulation of nuclear factor-kappaB, and steroid hormone receptors. Int. J. Oncol. 26, 785-792.
68. Chiu, L. C., Tong, K. F., and Ooi, V. E. ( 2005) Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells. Biomed. Pharmacother. 59 Suppl 2, S293-297.
69. Coward, L., Barnes, N. C., Setchell, K. D. R., and Barnes, S. ( 1993) Genistein, Daidzein, and Their Beta-Glycoside Conjugates - Antitumor Isoflavones in Soybean Foods from American and Asian Diets. J. Agr. Food Chem. 41, 1961-1967.
70. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Itoh, N., Shibuya, M., and Fukami, Y. ( 1987) Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 262, 5592-5595.
71. Banerjee, S., Li, Y., Wang, Z., and Sarkar, F. H. ( 2008) Multi-targeted therapy of cancer by genistein. Cancer Lett. 269, 226-242.
72. Horia, E., and Watkins, B. A. ( 2007) Complementary actions of docosahexaenoic acid and genistein on COX-2, PGE2 and invasiveness in MDA-MB-231 breast cancer cells. Carcinogenesis 28, 809-815.
73. Brouk, B. ( 1975) Plants Consumed by Man. Academic Press, New York.
74. Maheshwari, R. K., Singh, A. K., Gaddipati, J., and Srimal, R. C. ( 2006) Multiple biological activities of curcumin: a short review. Life Sci. 78, 2081-2087.
75. Shishodia, S., Chaturvedi, M. M., and Aggarwal, B. B. ( 2007) Role of curcumin in cancer therapy. Curr. Probl. Cancer 31, 243-305.
76. Saw, C. L., Huang, Y., and Kong, A. N. ( 2010) Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid. Biochem. Pharmacol. 79, 421-430.
77. Altenburg, J. D., Bieberich, A. A., Terry, C., Harvey, K. A., Vanhorn, J. F., Xu, Z., Davisson, V. J., and Siddiqui, R. A. ( 2011) A synergistic antiproliferation effect of curcumin and docosahexaenoic acid in SK-BR-3 breast cancer cells: unique signaling not explained by the effects of either compound alone. BMC Cancer 11, 149.
78. Istfan, N. W., Person, K. S., Holick, M. F., and Chen, T. C. ( 2007) 1alpha, 25-Dihydroxyvitamin D and fish oil synergistically inhibit G1/S-phase transition in prostate cancer cells. J. Steroid Biochem. Mol. Biol. 103, 726-730.
79. Chiang, K. C., Persons, K. S., Istfan, N. W., Holick, M. F., and Chen, T. C. ( 2009) Fish oil enhances the antiproliferative effect of 1alpha, 25-dihydroxyvitamin D3 on liver cancer cells. Anticancer Res. 29, 3591-3596.
80. Krishnan, A. V., Trump, D. L., Johnson, C. S., and Feldman, D. ( 2010) The role of vitamin D in cancer prevention and treatment. Endocrinol. Metab. Clin. North Am. 39, 401-418, table of contents.
81. Gederaas, O. A., Schonberg, S. A., Ramstad, S., Berg, K., Johnsson, A., and Krokan, H. E. ( 2005) Cell specific effects of polyunsaturated fatty acids on 5-aminolevulinic acid based photosensitization. Photochem. Photobiol. Sci. 4, 383-389.
82. Clark, L. C. ( 1985) The epidemiology of selenium and cancer. Fed. Proc. 44, 2584-2589.
83. Ip, C. ( 1998) Lessons from basic research in selenium and cancer prevention. J. Nutr. 128, 1845-1854.
84. Narayanan, B. A., Narayanan, N. K., Desai, D., Pittman, B., and Reddy, B. S. ( 2004) Effects of a combination of docosahexaenoic acid and 1, 4-phenylene bis(methylene) selenocyanate on cyclooxygenase 2, inducible nitric oxide synthase and beta-catenin pathways in colon cancer cells. Carcinogenesis 25, 2443-2449.
85. Ip, C., Carter, C. A., and Ip, M. M. ( 1985) Requirement of essential fatty acid for mammary tumorigenesis in the rat. Cancer Res. 45, 1997-2001.
86. Roebuck, B. D., Longnecker, D. S., Baumgartner, K. J., and Thron, C. D. ( 1985) Carcinogen-induced lesions in the rat pancreas: effects of varying levels of essential fatty acid. Cancer Res. 45, 5252-5256.
87. Fischer, S. M., Conti, C. J., Locniskar, M., Belury, M. A., Maldve, R. E., Lee, M. L., Leyton, J., Slaga, T. J., and Bechtel, D. H. ( 1992) The effect of dietary fat on the rapid development of mammary tumors induced by 7, 12-dimethylbenz(a)anthracene in SENCAR mice. Cancer Res. 52, 662-666.
88. Connolly, J. M., Liu, X. H., and Rose, D. P. ( 1996) Dietary linoleic acid-stimulated human breast cancer cell growth and metastasis in nude mice and their suppression by indomethacin, a cyclooxygenase inhibitor. Nutr. Cancer 25, 231-240.
89. Rose, D. P., Connolly, J. M., Rayburn, J., and Coleman, M. ( 1995) Influence of diets containing eicosapentaenoic or docosahexaenoic acid on growth and metastasis of breast cancer cells in nude mice. J. Natl Cancer Inst. 87, 587-592.
90. Rose, D. P., Connolly, J. M., and Coleman, M. ( 1996) Effect of omega-3 fatty acids on the progression of metastases after the surgical excision of human breast cancer cell solid tumors growing in nude mice. Clin. Cancer Res. 2, 1751-1756.
91. Kansal, S., Negi, A. K., Kaur, R., Sarotra, P., Sharma, G., Aggarwal, R., and Agnihotri, N. ( 2011) Evaluation of the role of oxidative stress in chemopreventive action of fish oil and celecoxib in the initiation phase of 7, 12-dimethyl benz(alpha)anthracene-induced mammary carcinogenesis. Tumour Biol. 32, 167-177.
92. Shao, Y., Pardini, L., and Pardini, R. S. ( 1995) Dietary menhaden oil enhances mitomycin C antitumor activity toward human mammary carcinoma MX-1. Lipids 30, 1035-1045.
93. Shao, Y., Pardini, L., and Pardini, R. S. ( 1997) Intervention of transplantable human mammary carcinoma MX-1 chemotherapy with dietary menhaden oil in athymic mice: increased therapeutic effects and decreased toxicity of cyclophosphamide. Nutr. Cancer 28, 63-73.
94. Wynter, M. P., Russell, S. T., and Tisdale, M. J. ( 2004) Effect of n-3 fatty acids on the antitumour effects of cytotoxic drugs. In Vivo 18, 543-547.
95. Ogilvie, G. K., Fettman, M. J., Mallinckrodt, C. H., Walton, J. A., Hansen, R. A., Davenport, D. J., Gross, K. L., Richardson, K. L., Rogers, Q., and Hand, M. S. ( 2000) Effect of fish oil, arginine, and doxorubicin chemotherapy on remission and survival time for dogs with lymphoma: a double-blind, randomized placebo-controlled study. Cancer 88, 1916-1928.
96. Cha, M. C., Meckling, K. A., and Stewart, C. ( 2002) Dietary docosahexaenoic acid levels influence the outcome of arabinosylcytosine chemotherapy in L1210 leukemic mice. Nutr. Cancer 44, 176-181.
97. Manni, A., Xu, H., Washington, S., Aliaga, C., Cooper, T., Richie, J. P., Jr., Bruggeman, R., Prokopczyk, B., Calcagnotto, A., Trushin, N., Mauger, D., Verderame, M. F., El-Bayoumy, K. ( 2010) The impact of fish oil on the chemopreventive efficacy of tamoxifen against development of N-methyl-N-nitrosourea-induced rat mammary carcinogenesis. Cancer Prev. Res. (Phila) 3, 322-330.
98. Colas, S., Paon, L., Denis, F., Prat, M., Louisot, P., Hoinard, C., Le Floch, O., Ogilvie, G., and Bougnoux, P. ( 2004) Enhanced radiosensitivity of rat autochthonous mammary tumors by dietary docosahexaenoic acid. Int. J. Cancer 109, 449-454.
99. Colas, S., Germain, E., Arab, K., Maheo, K., Goupille, C., and Bougnoux, P. ( 2005) Alpha-tocopherol suppresses mammary tumor sensitivity to anthracyclines in fish oil-fed rats. Nutr. Cancer 51, 178-183.
100. Swamy, M. V., Citineni, B., Patlolla, J. M., Mohammed, A., Zhang, Y., and Rao, C. V. ( 2008) Prevention and treatment of pancreatic cancer by curcumin in combination with omega-3 fatty acids. Nutr. Cancer 60 Suppl 1, 81-89.
101. Dufour, P., Mors, R., Berthaud, P., Lamy, T., Bergerat, J. P., Herbrecht, R., Maloisel, F., Audhuy, B., Lioure, B., Giron, C., Hurteloup, P., and Oberling, F. ( 1996) Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphoma. Leuk. Lymphoma 22, 329-334.
102. Kern, W., Schleyer, E., Unterhalt, M., Wormann, B., Buchner, T., and Hiddemann, W. ( 1997) High antileukemic activity of sequential high dose cytosine arabinoside and mitoxantrone in patients with refractory acute leukemias. Results of a clinical phase II study. Cancer 79, 59-68.
103. Atkinson, T. G., Murray, L., Berry, D. M., Ruthig, D. J., Meckling-Gill, K. A. ( 1997) DHA feeding provides host protection and prevents fibrosarcoma-induced hyperlipidemia while maintaining the tumor response to araC in Fischer 344 rats. Nutr. Cancer 28, 225-235.
104. Inomata, A., Horii, I., and Suzuki, K. ( 2002) 5-Fluorouracil-induced intestinal toxicity: what determines the severity of damage to murine intestinal crypt epithelia? Toxicol Lett. 133, 231-240.
105. Gomez de Segura, I. A., Valderrabano, S., Vazquez, I., Vallejo-Cremades, M. T., Gomez-Garcia, L., Sanchez, M., de Miguel, E. ( 2004) Protective effects of dietary enrichment with docosahexaenoic acid plus protein in 5-fluorouracil-induced intestinal injury in the rat. Eur. J. Gastroenterol. Hepatol. 16, 479-485.
106. Coleman, L. J., Landstrom, E. K., Royle, P. J., Bird, A. R., and McIntosh, G. H. ( 2002) A diet containing alpha-cellulose and fish oil reduces aberrant crypt foci formation and modulates other possible markers for colon cancer risk in azoxymethane-treated rats. J. Nutr. 132, 2312-2318.
107. Santos, N. A., Catao, C. S., Martins, N. M., Curti, C., Bianchi, M. L., and Santos, A. C. ( 2007) Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch. Toxicol. 81, 495-504.
108. El-Mesery, M., Al-Gayyar, M., Salem, H., Darweish, M., El-Mowafy, A. ( 2009) Chemopreventive and renal protective effects for docosahexaenoic acid (DHA): implications of CRP and lipid peroxides. Cell Div. 4, 6.
109. Brown, T. T., Zelnik, D. L., and Dobs, A. S. ( 2003) Fish oil supplementation in the treatment of cachexia in pancreatic cancer patients. Int. J. Gastrointest. Cancer 34, 143-150.
110. Colomer, R., Moreno-Nogueira, J. M., Garcia-Luna, P. P., Garcia-Peris, P., Garcia-de-Lorenzo, A., Zarazaga, A., Quecedo, L., del Llano, J., Usan, L., and Casimiro, C. ( 2007) N-3 fatty acids, cancer and cachexia: a systematic review of the literature. Br. J. Nutr. 97, 823-831.
111. van Norren, K., Kegler, D., Argiles, J. M., Luiking, Y., Gorselink, M., Laviano, A., Arts, K., Faber, J., Jansen, H., van der Beek, E. M., van Helvoort, A. ( 2009) Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice. Br. J. Cancer 100, 713-722.
112. Bougnoux, P., Hajjaji, N., Baucher, M. A., Jourdan, M. L., Goupille, C., Body, G., Le Floch, O. ( 2006) Docosahexaenoic acid (DHA) intake during first line chemotherapy improves survival in metastatic breast cancer. Proc. Am. Assoc. Cancer Res. 47, 1237 [Abstract 5276].
113. Connolly, J. M., Liu, X. H., and Rose, D. P. ( 1997) Effects of dietary menhaden oil, soy, and a cyclooxygenase inhibitor on human breast cancer cell growth and metastasis in nude mice. Nutr. Cancer 29, 48-54.